Statins Cut Heart Risk in Older Adults
A major Australian clinical trial has found that daily statin treatment reduced the risk of a first major cardiovascular event by 30% among otherwise healthy adults over 70. The findings could influence future guidelines on preventive cardiovascular care for older people.
Rethinking Prevention After 70
A large Australian clinical trial has provided new evidence about the use of statins in healthy older adults. Researchers found that daily statin treatment reduced the risk of a first major cardiovascular event by 30% among people aged over 70 who had no previous cardiovascular disease, diabetes or dementia.
The study addresses a longstanding gap in medical evidence. Statins are widely used to reduce cardiovascular risk, but older adults have historically been underrepresented in major clinical trials. This has left physicians with less certainty about whether preventive treatment should routinely be extended to otherwise healthy people in their seventies and beyond.
Nearly 10,000 Australians participated in the decade-long research programme, with participants receiving either daily statin therapy or a placebo. Researchers found that one major cardiovascular event could be prevented for approximately every 37 people treated over almost six years.
The findings could have important consequences for healthcare systems facing rapidly ageing populations. Cardiovascular disease remains one of the major causes of illness and death among older adults, meaning even relatively modest reductions in risk could translate into substantial public-health benefits when applied across large populations.
At the same time, the findings require careful interpretation. The study did not show an improvement in disability-free survival, meaning that reducing heart attacks and strokes did not necessarily translate into longer periods of life without disability. More than 15% of participants also stopped taking the medication during the trial.
The study may nevertheless encourage medical organisations to reconsider existing prevention guidelines. Its broader importance lies in providing stronger evidence for a population that has often been excluded from preventive research.
The debate surrounding statins is therefore shifting from whether they work in older adults to a more complex question: which older adults are most likely to benefit, and how should cardiovascular prevention be balanced against the realities of ageing?
Related Topics
Ipek Tuncer
Contributing writer at EUReflect.
Follow EUReflect
See more of our reporting on Google
Mark EUReflect as a preferred source and our stories are ranked higher for you in Top Stories, Discover and Google News — and carry a “preferred” badge when they are cited in AI results.
Add EUReflect as a preferred source
